Antimicrobial nanocoatings show strong potential, achieving >3-log10 bacterial reductions and reducing corneal infiltrative events in trials. Future work should focus on hybrid, stimuli-responsive coatings that activate under infection-specific conditions, ensure long-term safety, and meet manufacturing and regulatory requirements.
Sara et al. (Thu,) studied this question.